Stock MDGL MADRIGAL PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Madrigal Pharmaceuticals, Inc.

Equities

MDGL

US5588681057

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-08 EDT 		5-day change 1st Jan Change
208 USD -4.55% Intraday chart for Madrigal Pharmaceuticals, Inc. -1.21% -10.09%
05-07 Sector Update: Health Care Stocks Steady Pre-Bell Tuesday MT
05-07 Madrigal Pharmaceuticals Q1 Loss Widens; Shares Fall Pre-Bell MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Madrigal: Q1 Earnings Snapshot
AQ
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
AQ
Nonalcoholic Steatohepatitis Market to Observe Impressive Growth During the Forecast Period | Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Eli Lilly and Company, Madrigal Pharmaceuticals
AQ
Madrigal Statement on the Passing of Dr. Stephen Harrison
AQ
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
AQ
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
AQ
6 Stocks Positioned to Soar as Investors Focus on MASH
AQ
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
AQ
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
AQ
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
AQ
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
AQ
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
AQ
Madrigal Pharmaceuticals Announces Proposed Public Offering
AQ
Adobe, Ulta Beauty fall; Madrigal, Intuitive Surgical rise, Friday, 3/15/2024
AQ
Madrigal Pharmaceuticals : Rezdiffra Approval Presentation
PU
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
AQ
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
AQ
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis
AQ
Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer
AQ
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MDGL Stock
  4. News Madrigal Pharmaceuticals, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW